Introduction
============

Sodium valproate (SV) has a simple chemical structure, and it offers anticonvulsant and mood stabilizing properties. We present the first case, to our knowledge, of a pediatric bipolar patient who developed diurnal and nocturnal enuresis during treatment with SV.

Case report
===========

"Z," a 14-year-old girl, was referred to our child psychiatry clinic because she was experiencing a mania episode. Both a magnetic resonance imaging scan and an electroencephalography revealed no hint of an organic cause of her manic symptoms. Since her history also revealed a depressive episode, she was diagnosed as having bipolar disorder type 1 using the Kiddie-Sads-Present and Lifetime Version.[@b1-ndt-9-1671] Then, the Young Mania Rating Scale[@b2-ndt-9-1671] was used to measure the severity of her manic symptoms; her score was 45.

We started treatment with SV 250 mg/day for the first 4 days. We also administered risperidone 1 mg/day to resolve the ideas of reference symptom throughout the course of treatment. At the 15th day, the dose of SV was titrated to 750 mg/day (250 mg at noon and 500 mg at night). Since the SV dose reached 750mg/day Z began bedwetting. About 4 weeks later, when the dose of SV was titrated up to 500mg twice a day (a blood level of 75μg/ml), Z developed diurnal and nocturnal enuresis every day at the fifth week, she even had urinary incontinence in the classroom at school.

Z had not taken SV before, and her personal history revealed that she achieved urinary bladder control at 4 years old; since then, she had had no urinary incontinence. The family history was negative for enuresis, and urological and neurological evaluations were normal. Because of the enuresis, the SV dose was reduced to 500 mg/day (a blood level of 38.3 μg/mL), and her bedwetting disappeared completely 2 days later. At her follow-up visit half a year later, she appeared to be well adjusted to the treatment, which consisted of SV at 500 mg/night and risperidone 1 mg/day.

Discussion
==========

Enuresis is a common problem that can be troubling for children and their families. The causes mostly include functional impairments, such as bladder dysfunction. Previous studies have claimed that risperidone may induce enuresis.[@b3-ndt-9-1671],[@b4-ndt-9-1671] However, the girl had taken risperidone 1 mg/day throughout the course of her treatment in our case. Furthermore, enuresis appeared with the increased dosage of SV and disappeared with the decreased dosage of SV. Therefore SV, but not risperidone, was related to bedwetting in the present study.

Our literature search identified 14 case reports that described the induction of enuresis in children with epilepsy who were treated with SV, but there was an absence of literature examining nonepileptic patients.[@b4-ndt-9-1671]--[@b9-ndt-9-1671] Moreover, none of the patients presented with diurnal enuresis. In line with these case reports, Z's symptoms disappeared after dose reduction, indicating a dose-related side effect.[@b5-ndt-9-1671]--[@b9-ndt-9-1671] An explanation for the exacerbation of enuresis during SV treatment remains speculative.

According to Choonara,[@b7-ndt-9-1671] two of the most likely explanations include that enuresis is a consequence of increased depth of sleep,[@b7-ndt-9-1671],[@b8-ndt-9-1671] or that enuresis is secondary to a central effect that occurs on the thirst center, resulting in polydipsia.[@b7-ndt-9-1671] Increased thirst has been demonstrated in several studies with SV.[@b10-ndt-9-1671],[@b11-ndt-9-1671] In addition, SV may induce changes in renal tubules.[@b8-ndt-9-1671] However, the hypothesis of increased depth of sleep as a cause does not seem to explain the daytime enuresis symptom experienced by Z in the present study. In any case, clinicians may wish to be vigilant about this adverse effect when treating pediatric patients with SV, as the side effect can be detrimental to treatment adherence.
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